MammaPrint™ 70-gene signature: another milestone in personalized medical care for breast cancer patients

References

• Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist13, 477–493 (2008).
   PubMed Web of Science ®Google Scholar
• Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res.11, 205 (2009).
   PubMedGoogle Scholar
• van ‘t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415, 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• Ross JS, Linette GP, Stec J et al. Breast cancer biomarkers and molecular medicine. Expert Rev. Mol. Diagn.3, 573–585 (2003).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst.98, 262–272 (2006).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406, 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin. Oncol.34, S10–S16 (2007).
   PubMed Web of Science ®Google Scholar
• Stec J, Wang J, Coombes K et al. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J. Mol. Diagn.7, 357–367 (2005).
   PubMed Web of Science ®Google Scholar
• Gruvberger-Saal SK, Cunliffe HE, Carr KM et al. Microarrays in breast cancer research and clinical practice – the future lies ahead. Endocr. Relat. Cancer13, 1017–1031 (2006).
   PubMed Web of Science ®Google Scholar
• Ross JS, Symmans WF, Pusztai L et al. Breast cancer biomarkers. Adv. Clin. Chem.40, 99–125 (2005).
   PubMed Web of Science ®Google Scholar
• van ‘t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415, 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• Buyse M, Loi S, van ‘t Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst98, 1183–1192 (2006).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van ‘t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347, 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Bueno-de-Mesquita JM, Keijzer R, Linn SC et al. A new independent validation of the 70-gene signature in node-negative breast cancer. Eur. J. Cancer4, 131 (2006).
   Google Scholar
• Bueno-de-Mesquita JM, van Hartren WH, Retel VP et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol.8, 1079–1087 (2007).
   PubMed Web of Science ®Google Scholar
• Wittner BS, Sgroi DC, Ryan PD et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin. Cancer Res.14, 2988–2993 (2008).
   PubMed Web of Science ®Google Scholar
• Mook S, Schmidt MK, Viale G et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. DOI: 10.1007/s10549-008-0130-2 (2008) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Cardoso F, van ’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol.26, 729–735 (2008).
   PubMed Web of Science ®Google Scholar
• Mook S, Van’t veer LJ, Rutgers E et al. Individualization of therapy using MammaPrint: From development to the MINDACT trial. Cancer Genomics Proteomics4, 147–155 (2007).
   PubMedGoogle Scholar
• Bogaerts J, Cardoso F, Buyse M et al. Prospective evaluation of a gene signature as a new prognostic tool in early stage breast cancer: background and challenges in the design of MINDACT (Microarray In Node Negative Disease May Avoid Chemotherapy Trial). Nat. Clin. Pract. Oncol.3, 540–551 (2006).
   PubMedGoogle Scholar
• Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol.24, 3726–3734 (2006).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351, 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol.4, 603–610 (2008).
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol.27, 1160–1167 (2007).
   Web of Science ®Google Scholar
• Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer109, 1011–1018 (2007).
   PubMed Web of Science ®Google Scholar
• Mook S, Bonnefoi H, Pruneri G et al. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Eur. J. Cancer45, 1201–1208 (2009).
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Is molecular profiling ready for use in clinical decision making? Oncologist12, 301–311 (2007).
   PubMed Web of Science ®Google Scholar
• Jenssen TK, Hovig E. Gene-expression profiling in breast cancer. Lancet365, 634–635 (2005).
   PubMed Web of Science ®Google Scholar